FDA Determines Regulatory Review Period for Filsuvez Patent Extension
December 10, 2025
December 10, 2025
WASHINGTON, Dec. 10 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has finalized its determination of the regulatory review period for the human drug product Filsuvez, also known as birch triterpenes.
This determination is a required step following the submission of applications to the director of the Patent and Trademark Office for the extension of patents claiming the drug.
Filsuvez is indicated for the treatment of wounds ass . . .
This determination is a required step following the submission of applications to the director of the Patent and Trademark Office for the extension of patents claiming the drug.
Filsuvez is indicated for the treatment of wounds ass . . .